The Translational Research Core (TRC) is comprised of separate but related services devoted to supporting clinical research efforts.
The Pharmacology Section focuses on the pharmacokinetic (PK) analyses of anticancer drugs and their metabolites as part of early-phase clinical trials using liquid chromatography and liquid chromatography/tandem mass spectrometry. Pharmacokinetic modeling is an essential objective for investigators in early-phase trials and an ultimate goal for the TRC.
The Pharmacodynamic Section supports Moffitt researchers who conduct both preclinical and clinical research by providing services such as Western blot analyses, ELISA, or DNA-protein binding assays for molecular endpoint analyses, and vitro drug sensitivity assays for clinical correlative and preclinical studies.
Performs important laboratory assays in phase I and II clinical trials
- Performs important laboratory assays in phase I and II clinical trials
- Provides liquid chromatography/mass spectrometry assays for pre-clinical and clinical drug quantitation.
- Provides specialized sample purifications and/or extractions to facilitate the flow of clinical specimens to other assays in other core facilities in the Center.
- Uses high-throughput 384-well-based and 1536 well-based viability/apoptosis assays help researchers identify potential indications for investigational agents to inhibit cancer types
- Helps discovery of drug synergistic interactions.
TRC services include specialized sample processing for research specimens collected in clinical trials and a variety of pharmacologic, whole cell-based and molecular assays:
- Drug Quantitation
- Pharmacodynamic assays
- Drug response assays
- Additional services (e.g., apoptosis assays for investigators using nuclear staining or TUNEL methods, as well as RNase protection assays)
Core Facility Manager - Anthony Neuger, MS
Research Specialist - Samer Sansil, MS
Staff Scientist - Chris Cubitt, PhD
Research Specialist - Shumin Zhang, MD
Research Specialist - Ashley Blanchard, BS